Overall, the beneficial effects of BI 1015550 in two lung fibrosis models are in agreement with preclinical data in the literature that selective PDE4 inhibitors could be clinically effective not only in lung fibrosis but, based on animal data, probably also in fibrosis of other organs (e.g. liver, kidney, colon, and/or skin). The gene discussed is PDE4A; the disease is pulmonary fibrosis.